Blood-brain barrier tight junction disruption, increased permeability, and neuroinflammatory cascade in neurological disorders

Introduction

The blood-brain barrier stands as one of the body's most selective interfaces. Built from specialized endothelial cells linked by tight junction protein complexes-mainly claudin-5, occludin, and zonula occludens-1 (ZO-1)-the BBB restricts paracellular transport and shields neural tissue from circulating toxins and immune cells [1,2] . BBB disruption has been documented in stroke, traumatic brain injury, multiple sclerosis, and CNS infections [3,4] . The breakdown typically involves MMP-9 activation, which degrades tight junction proteins and basement membrane components [5] . Once the barrier opens, peripheral immune cells flood into brain parenchyma, triggering microglial activation. These glial cells release proinflammatory cytokines including TNF-α, IL-1β, and IL-6, which further damage tight junctions in a self-amplifying loop [6,7] . Serum S100B protein, an astrocyte-derived calcium-binding protein, has gained traction as a peripheral biomarker of BBB integrity [8] . The CSF albumin quotient (QAlb) is the gold standard for BBB permeability assessment but requires lumbar puncture [9] . Few investigations from the Middle East have combined tight junction quantification with both peripheral and CSF-based permeability markers across graded neurological severity [10,11] . This research measured tight junction protein levels, BBB permeability markers, and inflammatory cytokines in patients with varying neurological impairment at a clinical facility in Baghdad, Iraq.

severe (n=18, GOS-E 3), and mixed-diagnosis (n=20). Diagnoses included ischemic stroke (n=31), traumatic brain injury (n=19), multiple sclerosis (n=16), and CNS infections (n=22). Controls had no neurological history. Paired blood and CSF samples were obtained within 72 hours of admission.

Methods

Serum S100B was quantified by electrochemiluminescence immunoassay (Elecsys, Roche Diagnostics). CSF and serum albumin were measured by nephelometry, and QAlb was calculated as (CSF albumin / serum albumin) × 1000 [9] . Tight junction proteins (claudin-5, occludin, ZO-1) were measured in CSF by ELISA (Cusabio Biotech). Proinflammatory cytokines (TNF-α, IL-1β, IL-6) were quantified by multiplex immunoassay (Bio-Plex, Bio-Rad). MMP-9 was measured by gelatin zymography. The research was approved by the Ethics Committee of Baghdad Institute of Medical Sciences (Protocol BMS-EC-2023-061, May 2023); written informed consent was obtained from all participants. Statistical analysis used SPSS 27.0 with oneway ANOVA, Tukey post-hoc tests, and Pearson/Spearman correlations (p<0.05).

Results: Groups were comparable in age (mean 48.2-52.7 years) and sex distribution. .001 QAlb = CSF albumin quotient. Data as mean ± SD. All markers showed graded elevation from control through severe groups (all p<0.001, one-way ANOVA). Elevated CSF claudin-5 reflects tight junction protein shedding from disrupted endothelial junctions.

Comprehensive Interpretation

All biomarkers followed a clear severity gradient. S100B and QAlb showed the tightest correlation (r = 0.89), confirming serum S100B as a reliable non-invasive BBB integrity proxy. CSF claudin-5 levels rose with severity, indicating progressive tight junction disassembly. The cytokine pattern TNF-α leading is consistent with a TNF-αdriven cascade that amplifies barrier breakdown through MMP-9 upregulation.

Discussion

These data map a consistent relationship between BBB disruption severity and neuroinflammatory marker intensity. The strong S100B-QAlb correlation (r = 0.89) exceeds the 0.78 reported by Marchi and colleagues [8] in a Western cohort, possibly reflecting the higher proportion of acute conditions in our sample. The graded elevation of CSF claudin-5 across severity groups adds molecular-level evidence to the permeability measurements. Claudin-5 shedding into CSF indicates active tight junction degradation rather than merely increased paracellular passage [12] . The cytokine cascade pattern observed here-TNF-α showing the steepest gradient across severity groupssupports the model in which TNF-α acts as a master regulator of neuroinflammation. TNF-α activates NF-κB signaling in endothelial cells, which downregulates claudin-5 and occludin transcription while simultaneously upregulating MMP-9 [6,13] . This creates the feedback loop shown in Figure 2: barrier damage releases more inflammatory mediators, which cause further barrier damage. Breaking this cycle represents an attractive therapeutic target [14] . Serum MMP-9 was eight-fold higher in the severe group compared to controls and correlated with both QAlb (r = 0.82) and claudin-5 CSF levels (r = 0.79). MMP-9 directly cleaves tight junction proteins and collagen IV in the basement membrane, and its inhibition has shown barrierprotective effects in animal stroke models [15,16] .

Limitations

This research has notable constraints. The cross-sectional design captures a single time point and cannot track the temporal sequence of BBB breakdown and neuroinflammation. The heterogeneous patient populationspanning stroke, TBI, MS, and infections-limits diseasespecific conclusions. CSF sampling by lumbar puncture may not perfectly reflect BBB integrity at the cortical level. And the sample size, while adequate for detecting large effect sizes, limits the power to detect weaker associations within individual diagnostic subgroups [17] .

Conclusion

BBB tight junction disruption, reflected by elevated CSF claudin-5 and increased QAlb, scaled consistently with neuroinflammatory marker levels across severity groups. Serum S100B showed strong correlation with CSF-based permeability measures, supporting its use as a non-invasive BBB integrity marker. The TNF-α-driven inflammatory cascade, amplified through MMP-9-mediated tight junction degradation, operated as a self-reinforcing loop linking barrier breakdown to neuroinflammation. These findings from an Iraqi cohort support the concept that BBB-targeted interventions could interrupt the neuroinflammatory cycle in neurological conditions.

Acknowledgement

Acknowledgements Funding SourcesFunded by an institutional research grant from Baghdad

References

1. Abbott NJ, Patabendige AA, Dolman DE, Yusof SR, Begley DJ. Structure and function of the blood-brain barrier. Neurobiology of Disease. 2010;37(1):13-25.
2. Daneman R, Prat A. The blood-brain barrier. Cold Spring Harbor Perspectives in Biology. 2015;7(1):a020412.
3. Zlokovic BV. The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron. 2008;57(2):178-201.
4. Sweeney MD, Sagare AP, Zlokovic BV. Blood-brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders. Nature Reviews Neurology. 2018;14(3):133-150.
5. Rosenberg GA. Matrix metalloproteinases and their multiple roles in neurodegenerative diseases. Lancet Neurology. 2009;8(2):205-216.
6. Varatharaj A, Galea I. The blood-brain barrier in systemic inflammation. Brain, Behavior, and Immunity. 2017;60:1-12.
7. Liebner S, Dijkhuizen RM, Reiss Y, Plate KH, Agalliu D, Constantin G. Functional morphology of the bloodbrain barrier. Acta Neuropathologica. 2018;135(3):311336.
8. Marchi N, Cavaglia M, Fazio V, Bhudia S, Hallene K, Bhakta L. Peripheral markers of blood-brain barrier damage. Clinica Chimica Acta. 2004;342(1-2):1-12.
9. Reiber H. Proteins in cerebrospinal fluid and blood: barriers, CSF flow rate and source-related dynamics. Restorative Neurology and Neuroscience. 2003;21(34):79-96.
10. Al-Obaidi MM, Desa MN. Mechanisms of blood brain barrier disruption by different types of bacteria. BioMed Research International. 2018;2018:4759461.
11. Kadry H, Noober B, Bhargava K, Bhargava A. A blood-brain barrier overview on structure, function, impairment, and biomarkers. Fluids and Barriers of the CNS. 2020;17(1):69.
12. Greene C, Hanley N, Campbell M. Claudin-5: gatekeeper of neurological function. Fluids and Barriers of the CNS. 2019;16(1):3.
13. Aslam M, Ahmad N, Srivastava R, Hemmer B. TNFalpha induced NFκB signaling in blood-brain barrier endothelium. Journal of Neuroinflammation. 2012;9:14.
14. Obermeier B, Daneman R, Bhatt L, Bhatt L. Development, maintenance and disruption of the bloodbrain barrier. Nature Medicine. 2013;19(12):1584-1596.
15. Yang Y, Estrada EY, Thompson JF, Liu W, Rosenberg GA. Matrix metalloproteinase-mediated disruption of tight junction proteins in cerebral vessels. Journal of Cerebral Blood Flow and Metabolism. 2007;27(4):697709.
16. Turner RJ, Sharp FR. Implications of MMP9 for blood brain barrier disruption and hemorrhagic transformation following ischemic stroke. Frontiers in Cellular Neuroscience. 2016;10:56.
17. Nation DA, Sweeney MD, Montagne A, et al. Bloodbrain barrier breakdown is an early biomarker of human cognitive dysfunction. Nature Medicine. 2019;25(2):270-276.
18. Keaney J, Campbell M. The dynamic blood-brain barrier. FEBS Journal. 2015;282(21):4067-4079.
19. Engelhardt B, Sorokin L. The blood-brain and the blood-cerebrospinal fluid barriers: function and dysfunction. Seminars in Immunopathology. 2009;31(4):497-511.
20. Hawkins BT, Davis TP. The blood-brain barrier/neurovascular unit in health and disease. Pharmacological Reviews. 2005;57(2):173-185.
21. Montagne A, Barnes SR, Sweeney MD, et al. Bloodbrain barrier breakdown in the aging human hippocampus. Neuron. 2015;85(2):296-302.